MX2020009693A - Composiciones y metodos de uso de los activadores del canal kv7. - Google Patents
Composiciones y metodos de uso de los activadores del canal kv7.Info
- Publication number
- MX2020009693A MX2020009693A MX2020009693A MX2020009693A MX2020009693A MX 2020009693 A MX2020009693 A MX 2020009693A MX 2020009693 A MX2020009693 A MX 2020009693A MX 2020009693 A MX2020009693 A MX 2020009693A MX 2020009693 A MX2020009693 A MX 2020009693A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- channel activators
- compounds
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644932P | 2018-03-19 | 2018-03-19 | |
| US201862644902P | 2018-03-19 | 2018-03-19 | |
| US201862663438P | 2018-04-27 | 2018-04-27 | |
| US201862697198P | 2018-07-12 | 2018-07-12 | |
| PCT/US2019/023039 WO2019183148A1 (en) | 2018-03-19 | 2019-03-19 | Kv7 channel activators compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009693A true MX2020009693A (es) | 2021-01-08 |
Family
ID=67905138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009693A MX2020009693A (es) | 2018-03-19 | 2019-03-19 | Composiciones y metodos de uso de los activadores del canal kv7. |
| MX2023001153A MX2023001153A (es) | 2018-03-19 | 2020-09-17 | Composiciones y metodos de uso de los activadores del canal kv7. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001153A MX2023001153A (es) | 2018-03-19 | 2020-09-17 | Composiciones y metodos de uso de los activadores del canal kv7. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10851067B2 (enExample) |
| EP (1) | EP3768677A4 (enExample) |
| JP (2) | JP7757036B2 (enExample) |
| KR (3) | KR102868652B1 (enExample) |
| CN (6) | CN118955402A (enExample) |
| AU (3) | AU2019239955B2 (enExample) |
| BR (1) | BR112020018933A2 (enExample) |
| CA (1) | CA3093976A1 (enExample) |
| IL (2) | IL277419B2 (enExample) |
| MX (2) | MX2020009693A (enExample) |
| SG (1) | SG11202008030WA (enExample) |
| WO (1) | WO2019183148A1 (enExample) |
| ZA (1) | ZA202308070B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202300362T1 (it) * | 2014-09-12 | 2023-11-13 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7 |
| SG11202008030WA (en) * | 2018-03-19 | 2020-10-29 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
| BR112022004847A2 (pt) * | 2019-09-17 | 2022-06-07 | Knopp Biosciences Llc | Método para tratar uma doença ou distúrbio de neurodesenvolvimento |
| CN120435316A (zh) * | 2022-08-30 | 2025-08-05 | 拜奥海芬治疗学有限公司 | 包括金属通道激活剂和nmda受体拮抗剂的组合疗法 |
| EP4584250A4 (en) * | 2022-09-06 | 2026-02-25 | Biohaven Therapeutics Ltd | POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS |
| WO2025035066A1 (en) * | 2023-08-10 | 2025-02-13 | Biohaven Therapeutics Ltd. | Extended-release formulations of kv7.2/7.3 potassium channel activators |
| AU2024340894A1 (en) * | 2023-09-15 | 2026-04-02 | Biohaven Therapeutics Ltd. | Methods of treating epilepsy and related disorders with potent and selective potassium channel activators |
| WO2025103406A1 (zh) * | 2023-11-15 | 2025-05-22 | 南京明德新药研发有限公司 | 6并5杂芳基衍生物及其应用 |
| WO2025137661A1 (en) * | 2023-12-22 | 2025-06-26 | Biohaven Therapeutics Ltd. | Combination treatment of neurological disorders |
| WO2025198930A1 (en) * | 2024-03-18 | 2025-09-25 | Humanwell Pharmacuetical Us, Inc. | Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof |
| WO2026042005A1 (en) | 2024-08-18 | 2026-02-26 | Biohaven Therapeutics Ltd. | Prodrugs of benzimidazol-1,2-yl amide compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0772181B2 (ja) | 1989-06-26 | 1995-08-02 | 株式会社大塚製薬工場 | ベンズイミダゾール誘導体 |
| JPH0772181A (ja) | 1993-09-03 | 1995-03-17 | Advantest Corp | 電位波形測定方法および装置 |
| GB9413724D0 (en) | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
| US6855714B2 (en) | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| SE0301701D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| CA2607219A1 (en) * | 2005-05-18 | 2007-02-15 | Neuraxon, Inc. | Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity |
| CN101516873A (zh) * | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| CN101778833A (zh) | 2007-08-10 | 2010-07-14 | 日本曹达株式会社 | 含氮杂环化合物和有害生物防除剂 |
| ES2539714T3 (es) | 2007-11-22 | 2015-07-03 | Zenyaku Kogyo Kabushikikaisha | Dispersiones sólidas que comprenden un cuerpo amorfo compuesto por un compuesto antitumoral heterocíclico |
| GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
| AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| WO2010080503A1 (en) | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| AU2011275393B2 (en) | 2010-07-08 | 2014-04-10 | Pfizer Inc. | Piperidinyl pyrimidine amides as Kv7 potassium channel openers |
| SG10201505997TA (en) | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| WO2014145852A2 (en) * | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| US10471139B2 (en) | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| SMT202300362T1 (it) | 2014-09-12 | 2023-11-13 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7 |
| SG11202008030WA (en) * | 2018-03-19 | 2020-10-29 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
| BR112022004847A2 (pt) * | 2019-09-17 | 2022-06-07 | Knopp Biosciences Llc | Método para tratar uma doença ou distúrbio de neurodesenvolvimento |
-
2019
- 2019-03-19 SG SG11202008030WA patent/SG11202008030WA/en unknown
- 2019-03-19 CN CN202410835028.0A patent/CN118955402A/zh active Pending
- 2019-03-19 IL IL277419A patent/IL277419B2/en unknown
- 2019-03-19 CN CN202410805542.XA patent/CN119118926A/zh active Pending
- 2019-03-19 JP JP2020551340A patent/JP7757036B2/ja active Active
- 2019-03-19 KR KR1020247037753A patent/KR102868652B1/ko active Active
- 2019-03-19 CA CA3093976A patent/CA3093976A1/en active Pending
- 2019-03-19 IL IL310136A patent/IL310136A/en unknown
- 2019-03-19 WO PCT/US2019/023039 patent/WO2019183148A1/en not_active Ceased
- 2019-03-19 MX MX2020009693A patent/MX2020009693A/es unknown
- 2019-03-19 EP EP19772264.8A patent/EP3768677A4/en active Pending
- 2019-03-19 CN CN202410827103.9A patent/CN118955401A/zh active Pending
- 2019-03-19 CN CN202410840828.1A patent/CN118955403A/zh active Pending
- 2019-03-19 CN CN202410805545.3A patent/CN118955400A/zh active Pending
- 2019-03-19 US US16/358,642 patent/US10851067B2/en active Active
- 2019-03-19 BR BR112020018933-2A patent/BR112020018933A2/pt unknown
- 2019-03-19 KR KR1020207029659A patent/KR102731128B1/ko active Active
- 2019-03-19 KR KR1020257032902A patent/KR20250150168A/ko active Pending
- 2019-03-19 CN CN201980033266.7A patent/CN112771039A/zh active Pending
- 2019-03-19 AU AU2019239955A patent/AU2019239955B2/en active Active
-
2020
- 2020-09-17 MX MX2023001153A patent/MX2023001153A/es unknown
- 2020-10-22 US US17/077,068 patent/US11261162B2/en active Active
-
2022
- 2022-01-07 US US17/570,536 patent/US11724990B2/en active Active
-
2023
- 2023-06-20 US US18/338,096 patent/US12286408B2/en active Active
- 2023-08-21 ZA ZA2023/08070A patent/ZA202308070B/en unknown
- 2023-11-16 JP JP2023195267A patent/JP2024026104A/ja active Pending
- 2023-11-17 AU AU2023266373A patent/AU2023266373B2/en active Active
-
2024
- 2024-04-17 AU AU2024202496A patent/AU2024202496A1/en active Pending
-
2025
- 2025-03-29 US US19/094,862 patent/US20260062389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009693A (es) | Composiciones y metodos de uso de los activadores del canal kv7. | |
| ECSP20003147A (es) | Carboxamidas como moduladores de los canales de sodio | |
| CO2019000945A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| PE20221280A1 (es) | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| CO2019000943A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| MX2018014202A (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| MX2019001318A (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
| MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| CO2022005890A2 (es) | Formas cristalinas de estado sólido de un modulador selectivo de canales de potasio | |
| CO2019009060A2 (es) | Moduladores del canal de potasio | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| CL2022000639A1 (es) | Métodos de uso para activadores de canal kv7 | |
| MX383682B (es) | Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional. | |
| MX2020008060A (es) | Clozapina para el tratamiento de una enfermedad de celulas b impulsada por inmunoglobulina. | |
| MX2024010081A (es) | Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). | |
| MX2016005510A (es) | Profarmacos y moduladores de receptores nmda, sales y usos de estos. | |
| CL2022001426A1 (es) | Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina | |
| MX2024010078A (es) | Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). | |
| CO2021013311A2 (es) | Inhibidores del canal de potasio novedosos | |
| UA113233U (uk) | Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента | |
| UA113237U (uk) | Фармацевтична комбінація ацеклофенаку і снодійного або заспокійливого компонента |